Posted by Michael Wonder on 01 Jul 2022
US FDA seeks more information on Maxigesic IV application
1 July 2022 - Hyloris Pharmaceuticals announces that it has today received a complete response letter from the US FDA on its application for the US registration of Maxigesic IV.
The FDA has only requested additional data on one remaining topic.
